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Summary
In eukaryotic cells, the SH2 and PTB domains mediate
protein-protein interactions by recognizing phospho-
tyrosine residues on target proteins. Here we make
the unexpected finding that the C2 domain of PKC
directly binds to phosphotyrosine peptides in a se-
quence-specific manner. We provide evidence that
this domain mediates PKC interaction with a Src
binding glycoprotein, CDCP1. The crystal structure of
the PKC C2 domain in complex with an optimal
phosphopeptide reveals a new mode of phosphotyro-
sine binding in which the phosphotyrosine moiety
forms a ring-stacking interaction with a histidine resi-
due of the C2 domain. This is also the first example
of a protein Ser/Thr kinase containing a domain that
binds phosphotyrosine.
Introduction
Fifteen years ago, the discovery of Src homology 2
(SH2) domain interactions with phosphotyrosine pro-
teins established a new paradigm for signal transduc-
tion in which protein phosphorylation on tyrosine leads
to acute formation of multiprotein complexes. More
than 10 years ago, the discovery of a second family
of phosphotyrosine binding (PTB) domains unrelated to
SH2 domains revealed an independent evolution of this
important mechanism of signal transduction. Up to now
these two domains were the only known phosphotyro-
sine binding domains.
The C2 domains (C2 stands for conserved domain 2)
are eight β strand modules of about 120 amino acids
that are found in a large number of eukaryotic proteins
(Nalefski and Falke, 1996). C2 domains are found in all
eukaryotes, including yeast, but are not found in pro-
karyotes. Originally identified in classical/conventional
protein kinases C (PKC), they were found to mediate
calcium-dependent lipid binding. However, the resi-
dues required for calcium binding in classical PKCs and
other proteins are not found in all the C2 domains.
Nonetheless, for several of these proteins the C2 do-
main is still known to bind phospholipids (Rizo and
Sudhof, 1998). Several C2 domains have also been
shown to serve as protein-protein interaction domains*Correspondence: ssoltoff@bidmc.harvard.edu
1These authors contributed equally to this work.(Dekker and Parker, 1997; Gray et al., 1997; Ron et al.,
1995). Interestingly, in coordination with lipid binding
this could permit recruitment of the C2 domain-contain-
ing protein to specific membrane compartments (Mellor
and Parker, 1998). In the case of classical PKCs, bind-
ing of the C2 domain to the membrane is also important
to release the pseudosubstrate from the catalytic site
(Newton and Johnson, 1998).
The regulatory domain of the novel protein kinases C
(PKCδ, -, -θ, and -η) contains a tandem repeated C1
domain and a C2 domain that does not bind calcium.
Very recently it was shown that the C2 domain of PKCδ
does not bind to phospholipids (Stahelin et al., 2004).
PKCδ is known to bind to several proteins, including
actin, GAP-43, and possibly SRBC, via its C2 domain
(Dekker and Parker, 1997; Izumi et al., 1997; Lopez-
Lluch et al., 2001). PKCδ is also known to be regulated
by tyrosine phosphorylation downstream of Src (Benes
and Soltoff, 2001; Blake et al., 1999; Shanmugam et al.,
1998; Zang et al., 1997). Although several studies have
reported an interaction between Src and PKCδ (Shan-
mugam et al., 1998; Zang et al., 1997), the mechanism
underlying this interaction remains unclear.
The activity of Src is regulated by phosphorylation of
a tyrosine residue near the C terminus. This residue
binds to the SH2 domain of the same Src molecule,
thereby constraining the catalytic domain in an inactive
conformation (Sicheri et al., 1997; Xu et al., 1997).
Phosphorylation and engagement of the Src SH2 do-
main thus provide both a means for enzyme activation
and the targeting of the enzyme to a specific location
in the cell. Several multiprotein complexes containing
Src and other kinases have been identified, including
the PDGF receptor and focal adhesion kinase (FAK)
(DeMali et al., 1999; Hanks et al., 2003). CDCP1, a newly
identified transmembrane protein that is overexpressed
in colon cancer (Hooper et al., 2003; Scherl-Mostageer
et al., 2001), possesses several binding sites for the
Src SH2 domain. In the majority of colon cancers, Src
activity is upregulated, either by increases in its specific
activity or levels of expression (Irby et al., 1997; Irby et
al., 1999; Malek et al., 2002; Mao et al., 1997). Therefore
it was of interest that we found that CDCP1 was phos-
phorylated on tyrosine residues in a Src-dependent
manner, and this prompted us to examine this finding
in more detail.
Here we show that the C2 domain of PKCδ is a phos-
photyrosine binding domain. We determine its specific-
ity by peptide library screens, its affinity by isothermal
titration calorimetry, and the structural basis for phos-
photyrosine binding by X-ray diffraction of its crystal
structure. Our data indicate that Src phosphorylates
and binds to CDCP1 by its SH2 domain and the C2
domain of PKCδ binds to CDCP1, thus forming a multi-
protein complex that includes two important kinases.
Results
Several studies, including ours, have previously shown
that PKCδ is tyrosine phosphorylated and that its ki-
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272nase activity is regulated by Src in various cell types i
M(Benes and Soltoff, 2001; Blake et al., 1999; Denning et
al., 1996; Soltoff and Toker, 1995). In the hope of under- i
(standing the mechanisms of this regulation, we sought
to identify a 135 kDa tyrosine-phosphorylated protein C
mthat we found associated with PKCδ and Src in various
cell lines upon stimulation with phorbol ester (PMA, k
dphorbol-12-myristate-13-acetate) and addition of per-
vanadate, as well as in response to more physiologi- a
acally relevant conditions, such as muscarinic and pu-
rinergic receptor stimulation (Figure 1A). The use of C
mSrc-family kinase inhibitors (PP1, PP2) suggested that
p135 tyrosine phosphorylation was controlled by a Src
dfamily member (Figure 1B). Since we also found that
the regulatory domain (RD) of PKCδ (residues 1–332, l
yfused to glutathione S-transferase) bound to a tyrosine-
phosphorylated 135 kDa protein when cells were t
Itreated with PMA or pervanadate, we used this domain
(GST-RD PKCδ) as an affinity reagent to isolate p135 C
pfrom lysates of cells treated with pervanadate (Figure
1C). Using mass spectrometry we identified p135 as C
pCDCP1, a recently described transmembrane glycosy-
lated protein overexpressed in colon cancer (Scherl- s
kMostageer et al., 2001). The same protein has also beenFigure 1. Identification of a Phosphotyrosine
Protein Directly Binding to the C2 Domain
of PKCδ
Immunoblot analysis of proteins immuno-
precipitated from cell lysates and subjected
to SDS-PAGE.
(A) RPG1 (rat parotid gland 1) cells were left
untreated in growing medium or were
treated with PMA (PMA, 100 M for 2, 5, or
15 min, respectively), pervanadate (V, 100
M, 5 min), ATP (A, 100 M, 2 and 5 min),
UTP (U, 100 M, 2 and 5 min), and carbachol
(C, 100 M, 5 min).
(B) RPG1 cells were left untreated or treated
with pervanadate (PV, 100 M, 5 min) and/or
PP1 (PP1, 5 M, 30 min prior to PV).
(C) The 135 kDa protein that associates with
the regulatory domain of PKCδ is CDCP1.
Lysates from 108 A431 cells untreated or
treated with pervanadate (PV, 100 M, 15
min) were incubated with 50 g of GST-RD
PKCδ fusion protein, and bound proteins
were revealed by Coomassie staining. P135
was subsequently identified as CDCP1 using
mass spectrometry analysis on tryptic pep-
tides extracted from the gel.
(D) A431 cells were stimulated as indicated
and the lysates were either immunoprecipi-
tated with an anti-CDCP1 antibody or sub-
jected to a pull-down with GST-RD PKCδ fu-
sion protein.
(E and F) HCT116 cells were treated with hy-
drogen peroxide (H, 5 mM, 2, 5, or 10 min),
pervanadate (PV, 100 M, 5 min), and PMA
(PM, 100 nM, 5 min). For all blots, proteins
were immunoprecipitated and immunoblot-
ted as indicated.dentified as SIMA135 (subtractive immunization
(+)HEp3-associated 135 kDa protein) by subtractive
mmunization using a highly metastatic tumor cell line
Hooper et al., 2003). Although the predicted size of
DCP1 is 92 kDa, glycosylation increases its apparent
olecular weight in SDS-PAGE to approximately 135
Da (Hooper et al., 2003; Scherl-Mostageer et al., 2001;
ata not shown). By performing immunoprecipitation
nd pull-down in parallel, we determined that there is
correlation between the tyrosine phosphorylation of
DCP1 and its ability to interact with the regulatory do-
ain of PKCδ (Figure 1D).
Since the treatment of several cell types with hy-
rogen peroxide (H2O2) initiates signaling events re-
ayed in part by PKCδ and involving tyrosine phosphor-
lation (Storz et al., 2004), we utilized H2O2 as an agent
o examine the relationship between CDCP1 and PKCδ.
n fact, H2O2 induced the association of PKCδ with
DCP1 (Figure 1E). This association of endogenous
roteins correlates with the tyrosine phosphorylation of
DCP1, as seen in PKCδ immunoprecipitates and in
ull-downs using GST-RD (Figure 1F). Thus, the tyro-
ine phosphorylation of CDCP1 by several stimuli
nown to affect PKCδ and Src activation (or Src associ-
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with CDCP1.
The correlation between the tyrosine phosphorylation
of CDCP1 and an apparently direct association with the
regulatory domain of PKCδ suggested that the regula-
tory domain could contain a phosphotyrosine binding
domain. To test this possibility, a completely degener-
ated phosphotyrosine peptide library (XXXXpYXXXX,
where pY designates the phosphorylated tyrosine) was
screened against the GST-RD PKCδ fusion protein. The
results of this screen strongly suggested that the regu-
latory domain of PKCδ indeed bound specifically to ty-
rosine-phosphorylated peptides (Table 1). A subset of
peptides containing a tyrosine or phenylalanine residue
three residues C-terminal to the phosphorylated tyro-
sine was preferentially selected. We then screened a
second library containing a fixed tyrosine residue at +3
(XXXXpYXXYX) to obtain more detailed amino acid
preferences at other positions. The result of these li-
brary screens characterized the regulatory domain of
PKCδ as containing a phosphotyrosine binding domain
that has a strong preference for aromatic residues three
amino acids C-terminal to the phosphorylated tyrosine,
with the following consensus sequence (Table 1): (Y/F)-
(S/A)-(V/I)-pY-(Q/R)-X-(Y/F)-X.
Since several reports indicated that the PKCδ C2 do-
main was responsible for protein-protein interactions,
we investigated whether the C2 domain of PKCδ was
sufficient for the binding to CDCP1. Notably, the C2 do-
main alone (the folding unit encompassing residues 1
to 123, as defined by the previously solved crystal
structure of the free C2 domain [Pappa et al., 1998])
was able to pull down CDCP1 expressed in U2-OS cells
(Figure 2A).
To confirm that the C2 domain of PKCδ itself is a
phosphotyrosine binding domain that can pull down
CDCP1, a biotinylated version of the optimal peptide
defined by the library screens (Biotin-GGALYSIpYQ
PYVFAKKK) was used as bait for in vitro-translated
fragments of PKCδ. We found that the C2 domain of
PKCδ bound strongly to the phosphorylated version of
the optimal peptide but only very weakly to the non-
phosphorylated version (Figure 2B). When an XXXpYX
XYX biotinylated library was used, the same phospho-
dependency was shown. As a control, we showed that
an incomplete C2 domain (denoted C2*) that misses a
β strand essential to fold properly (Pappa et al., 1998)Table 1. Phosphotyrosine Peptide Motif Selection by the Regulatory Domain of PKCδ
−3 −2 −1 +1 +2 +3 +4
Y (1.4) S (1.6) V (1.3) pY Q (1.4) X Y (2.8) V (1.2)
F (1.3) A (1.3) I (1.2) R (1.4) F (1.8)
M (1.4) W (1.7)
V (1.3)
Y (1.4) S (1.7) I (1.5) pY Q (1.8) P (1.3) Y V (1.4)
F (1.2) A (1.7) V (1.4) R (1.8) I (1.4)
L (1.2) I (1.5) F (1.3)
M (1.2) V (1.5) L (1.2)
M (1.4)
A GST fusion of the regulatory domain (residues 1–332) of PKCδ was screened for binding to phosphopeptide libraries containing the
sequences MAXXXXpYXXXXAKKK and MAXXXXpYXXYXXAKKK, where X indicates all amino acids except Cys and pY denotes
phosphotyrosine. Residues showing strong enrichment are in italics.does not bind to the optimal phosphopeptide. Under
the same conditions, a short version of the C2 domain
(residues 1–123) also binds to the phosphopeptide
(data not shown).
Competition experiments showed that the phosphor-
ylated version of the optimal peptide could block the
interaction of the PKCδ C2 domain with multiple phos-
photyrosine proteins, including CDCP1, with an appar-
ent IC50 of about 500 nM (Figure 2C). The affinity of
the C2 domain for the optimal peptide was determined
using isothermal titration calorimetry. These experi-
ments showed that the dissociation constant for the
optimal phosphopeptide is less than 250 nM (the high-
est value from three independent determinations) and
the stoichiometry of the interaction is 1 mole phospho-
peptide per mole of C2 domain (Figure 2D). This affinity
is comparable to affinities reported for binding of opti-
mal phosphopeptides to SH2 and PTB domains (Paw-
son et al., 2001), the only two phosphotyrosine binding
domains previously described.
To give insight into the structural basis of the phos-
photyrosine binding property of the C2 domain, the
structure of the C2 domain from human PKCδ in com-
plex with the high-affinity phosphotyrosine peptide
(MALYSIpYQPYVFAKKK) was solved to a 1.7 Å resolu-
tion (Rcryst = 17.6%, Rfree = 22.1%; see data collection
and refinement statistics, Table 2). The overall C2 struc-
ture is very similar to that of the rat PKCδ C2 domain
(Pappa et al., 1998), with an rmsd of 0.49 Å from the
106 Cα atom. Thus, no significant difference in protein
structure is observed upon peptide binding (except for
deviations in the loop regions between β strand 1 and
2), analogous to what has been observed for the bind-
ing of phosphotyrosine peptides to SH2 and PTB do-
mains (Eck et al., 1996; Waksman et al., 1993). Electron
density for the associated phosphopeptide is clear
from Met−6 to Ala+6 (− positions are N-terminal to the
phosphotyrosine, Figure 3B). The peptide binds in an
extended conformation across one end of a β sheet
(strands 4, 1, 8, and 7), reaching the other β sheet
(strands 2, 5, and 6) (Figure 3A).
Most of the specificity of the peptide recognition
comes from the phosphotyrosine (pTyr) binding. It is
held in a deep pocket with extensive hydrogen bonds
(His62 side chain and backbone NH), electrostatic in-
teractions (Arg67 and Lys48 side chains), and van der
Waals interactions (ring stacking with His62) (Figures
Cell
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(A) U2-OS cells transfected with Src and CDCP1 were treated with pervanadate (100 M, 15 min) and the indicated pull-downs were per-
formed. RD: regulatory domain (residues 1–332); C2L: C2 domain long form (residues 1–160); C2S: C2 domain short form (residues 1–123).
(B) The C2 domain of PKCδ (C2L residues 1–160) was in vitro transcribed and translated in the presence of 35S Met and incubated with the
phosphorylated or unphosphorylated biotinylated optimal peptide (Opt) (GGALYSIpYQPYVFAKKK) or the XXXpYXXYX biotinylated peptide
library (Lib) bound to avidin beads. Bound radioactive material was revealed by autoradiography.
(C) HCT116 cells were stimulated with pervanadate (100 M) for 15 min and lysates were incubated with a GST-C2 fusion protein that had
been previously incubated with increasing concentration of phosphorylated or nonphosphorylated optimal peptide (0.01, 0.1, 0.5, 1, 5, 10 M).
(D) The affinity of the optimal phosphopeptide (GGALYSIpYQPYVFAKKK) for binding to the C2 domain of PKCδ was determined by isothermal
titration calorimetry using the GST-C2L PKCδ (1–160) fusion protein. Left, phosphopeptide; right, nonphosphopeptide. Fitting of the experi-
mental data with a one-type-of-site binding model gave a binding stoichiometry of 1.08 with dissociation constant (KD) of 240 nM at 25°C
(H = −1.4 × 104, S = −16.8, X2 = 26,631).3C and 3D). In addition, the two backbone amides c
caround the pTyr have direct H bonds to two conserved
residues in PKCδ, Asp60 and Glu123, helping to posi- p
stion the pTyr into the positive pocket. Notably, a phos-
phoserine or phosphothreonine side chain would likely u
sbe too short to reach Arg67 at the bottom of this
pocket. r
TThe rest of the peptide forms several backbone con-
tacts with the protein either directly or indirectly i
Cthrough water molecules, as well as side chain interac-
tions that explain some of the peptide library results b
n(Figure 3D). There are two direct peptide side chain re-
cognitions by the protein at Ser−2 and Tyr+3. The Ser−2 r
wside chain forms a hydrogen bond with the Arg6 guani-
dine head group of the C2 domain, and the Tyr+3 OH
uinteracts with the backbone amide of Tyr52. In addition,
the Tyr+3 aromatic ring stacks onto Met51 and interacts d
pwith Phe+5. Together they form a small hydrophobicluster that acts as a continuation of the hydrophobic
ore in between the two β sheets. This structure ex-
lains the peptide library data where the +3 position
howed strong preference for aromatic residues, partic-
larly tyrosine. Although the peptide library showed
ome selection for Gln at +1, there is no prominent
eason for this preference suggested by the structure.
he Gln side chain points into the solvent region and
nteracts with Thr58 indirectly through water molecules.
ompared to the other two known phosphotyrosine
inding domains, SH2 and PTB, which primarily recog-
ize residues either C-terminal or N-terminal to pTyr,
espectively, the PKCδ C2 domain interacts significantly
ith both ends of the peptide.
Phosphorylation on Tyr64 has been suggested to reg-
late PKCδ (Joseloff et al., 2002). Interestingly, this resi-
ue sits just outside of the positive binding pocket for
Tyr. Its OH is 5.46 Å from Arg67, compared to 5.20 Å
The PKCδ C2 Domain Binds Phosphotyrosine
275Table 2. Data Collection and Model Refinement Statistics
Data Collection
Space group P212121
Resolution (Å) 1.7 (1.76-1.70)a
Total reflections 67,012
Unique reflections 15,254
Completeness (%) 97.9 (92.9)
Rsym (%) 7.7 (18.6)
I/σ 18.9 (5.8)
Refinement
Non-H atoms 1229
Rcryst (%) 17.6
Rfree (%) 22.1
Mean B factor (Å2) 12.9
Rmsd bond lengths (Å) 0.010
Rmsd bond angles (°) 1.5
Rmsd B value (bonds) (Å2) 1.24
Rmsd B value (angles) (Å2) 1.65
Rsym = ΣhklΣirIi − <I>r/ΣhklΣi<I>.
Rcryst = ΣhklrFobs − Fcalcr/Fobs.
Rfree was calculated over the 6.8% of reflections not used for
model refinement.
a Values for the highest resolution shell are in parentheses.in the case of the equivalent OH on pTyr in the bound
peptide. When phosphorylated, Tyr64 would likely in-
teract electrostatically with Arg67, preventing the bind-
ing of phosphopeptides.
Coexpression experiments were used to determine
the mechanism of interaction between CDCP1, PKCδ,
and Src. Experiments using HEK293 or U2-OS cells
showed that PKCδ and Src associated robustly with
CDCP1 when the two kinases were coexpressed (Fig-
ure 4A). Moreover, the kinase activity of Src was neces-
sary for the interactions between Src and CDCP1 and
between PKCδ and CDCP1 to occur. When CDCP1 was
mutated at Tyr734, which is the most likely SH2 domain
binding site for Src (Yaffe et al., 2001) (http://scansite.
mit.edu), Src and PKCδ were also impaired in their abil-
ity to interact with CDCP1 (Figures 4B and 4C). Thus,
tyrosine phosphorylation of CDCP1 by Src appears to
promote the formation of a complex between CDCP1,
Src, and PKCδ.
The sequence surrounding Tyr762 of CDCP1
(VDTpYRPF) is in good agreement with the motif pre-
dicted to bind to the C2 domain of PKCδ and is also
predicted to be a good Src phosphorylation site (Song-
yang and Cantley, 1995a; Yaffe et al., 2001) (http://
scansite.mit.edu). We mutated Tyr762 to phenylalanine
and assessed the effects on the association of CDCP1
with Src and PKCδ. Coimmunoprecipitation and pull-
down experiments showed that the Y762F mutant of
CDCP1 is impaired in its association with PKCδ but not
with Src (Figures 5A and 5B). The regulatory domain of
PKCδ was able to pull down wild-type CDCP1 from
cells cotransfected with CDCP1, Src, and PKCδ (Figure
5B), but mutation of Tyr762 to phenylalanine led to a
clear decrease in CDCP1 pull-down, showing that
Tyr762 is likely to be the primary binding site of the
PKCδ C2 domain on CDCP1. A GST fusion protein of
the regulatory domain (SH2-SH3) of Src pulled down
wild-type CDCP1 but not the CDCP1 Y734F mutant
(Figure 5B), suggesting that the interaction between Srcand CDCP1 is stabilized mainly through an SH2-pY734
link. Although CDCP1 also contains a polyproline-rich
sequence susceptible to binding SH3 domains, the
same result was obtained using the Src SH2 domain
alone (data not shown). Another tyrosine residue
(Tyr743) is found in a favorable amino acid context to
be phosphorylated by Src (Yaffe et al., 2001). Using
phosphospecific antibodies (data not shown), we have
determined that this site is indeed phosphorylated in
these experiments, but this site does not appear to play
a significant role in the interaction of CDCP1 with either
Src or PKCδ (Figure 5B). Overall our data support a
model in which Src initiates phosphorylation of CDCP1
at Tyr734, associates through its SH2 domain at that
site, and promotes further phosphorylation at Tyr743
and Tyr762. Phosphorylation of Tyr762 results in the re-
cruitment of PKCδ to CDCP1. It is also possible that
direct contact between Src and PKCδ participates in
the formation of the complex since PKCδ wt or kinase
dead (KD) has a positive effect on the recruitment of
Src to CDCP1.
To confirm that in the context of the full-length pro-
tein the C2 domain is necessary for the interaction be-
tween PKCδ and CDCP1, a truncated version of PKCδ
was tested for its ability to interact with CDCP1. As
shown in Figure 5C, the mutant of PKCδ missing the C2
domain was unable to interact with CDCP1, but Src still
bound to CDCP1. Since His62 in the C2 domain seems
to play a major role in the interaction between the C2
domain and the phosphopeptide, we created a mutant
of PKCδ in which His62 was mutated into an aspartate.
We also mutated the Arg67 that appears to be crucial
for phosphate coordination. Mutation of either of these
residues was shown to abolish the interaction of PKCδ
with an optimal phosphopeptide (data not shown) or
with a phosphopeptide library linked to beads (Figure
5D). The lack of binding to a partially degenerate library
(XXXpYXXYXX) shows that the mutation of the residue
critical for tyrosine binding (His62) in the C2 domain
does not change the specificity of the C2 domain while
preserving phosphotyrosine binding. Importantly, in the
context of coexpression in cells, the mutant proteins
H62D PKCδ as well as R67S PKCδ are unable to in-
teract with CDCP1 (Figure 5E).
Discussion
Our studies show that PKCδ, a Ser/Thr protein kinase
identified more than 15 years ago, contains an unex-
pected phosphotyrosine binding domain. This domain
mediates the association of PKCδ with a transmem-
brane protein, CDCP1. The activity of the protoonco-
gene Src promotes this interaction by phosphorylating
key residues on CDCP1, and this leads to the formation
of a CDCP1-Src-PKCδ complex. In some instances
these results may explain how the previously observed
complex between PKCδ and Src occurs. It is also pos-
sible that direct interaction between the two kinases is
involved in complex formation or that cells that do not
express CDCP1 express analogous scaffold proteins.
The structure of the C2 domain of PKCδ in complex
with an optimal binding peptide reveals that the coordi-
Cell
276Figure 3. Crystal Structure of the C2 Domain of PKCδ in Complex with the Optimal Phosphopeptide
(A) Overall structure of the C2 domain of PKCδ bound to the phosphotyrosine peptide.
(B) Bottom view of the complex structure with composite-omit 2Fo − Fc map contoured at 1.2 σ around the peptide.
(C) Surface potential drawing of the C2 domain illustrating the deep positively charged pocket (blue) formed by Arg67 and Lys48 for phos-
phate binding.
(D) Schematic representation of interactions between the peptide, C2 domain, and water molecules (green spheres) at the interface. Peptide
backbone is in black and protein residues are in gray.
(E) Multiple sequence alignment of C2 domains from PKCδ (showing the conservation throughout evolution) and PKCθ (showing its potential
phosphotyrosine binding site). The residues that interact with the phosphate are highlighted in red and the residues that make contact with
the peptide are boxed.
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PKCδ, Src, and CDCP1
(A) U2-OS cells were transfected with plas-
mids encoding for FLAG-tagged CDCP1 wt,
EGFP-PKCδ wt or kinase dead (KD), and Src
wt or KD, as indicated. Phosphotyrosine pro-
teins as well as EGFP-PKCδ and Src were
detected in anti-FLAG immunoprecipitates
as indicated. (E.PKCδ: EGFP-PKCδ; similar
results were obtained using untagged
PKCδ). Right panel: total cell lysates corre-
sponding to lanes 5 and 6 of the left panel
showing lower expression of EGFP-PKCδ KD
compared to EGFP-PKCδ wt.
(B) U2-OS cells were transfected with plas-
mids encoding for FLAG-tagged CDCP1 wt
or CDCP1-Y734F mutant, EGFP-PKCδ, and
Src, as indicated. Phosphotyrosine proteins
as well as EGFP-PKCδ and Src were de-
tected in anti-FLAG immunoprecipitates as
indicated.
(C) U2-OS cells were transfected with plas-
mids encoding for FLAG-tagged CDCP1 wt
or CDCP1-Y734F mutant, EGFP-PKCδ, and
Src, as indicated. (E.PKCδ: EGFP-PKCδ;
similar results were obtained using untagged
PKCδ). Immunoprecipitations were per-
formed using anti-Src antibody (left) or anti-
PKCδ antibody (right).nation of the phosphate is achieved mainly through an
arginine residue, as in PTB and SH2 domains. Notably,
the interaction with the tyrosine is maintained by stack-
ing against a histidine residue, a mode of binding that
has not been observed in phosphotyrosine binding do-
mains. Importantly, the affinity of the peptide for the C2
domain is comparable to the affinities reported for SH2
and PTB domains with cognate peptides. Interestingly,
the binding site is close to the N and C termini of the
C2 domain; therefore, binding could potentially alter the
position of the domain relative to the rest of the protein.
Because the C2 domain is followed by the pseudosub-
strate region, binding of phosphotyrosine to the C2 do-
main could participate in activation of PKCδ as shown
for classical PKC when the C2 domain binds to lipids.
(For classical PKCs this event has to be followed by
binding of DAG to the C1 domain.) Numerous C2 do-
mains lack the amino acids residues necessary for
calcium binding. However, these calcium-insensitive
C2 domains are largely considered to be lipid binding
modules, although it has only been demonstrated for
a few of them (Pepio and Sossin, 2001). The crystal
structures of the C2 domains that have been solved
show, for the most part, a very similar fold. In that re-
spect it is interesting to note that the C2 domain of
PKCδ is significantly divergent from the other C2 do-mains only in the region in which we observed phos-
photyrosine binding situated on the opposite side of
where calcium and phospholipids bind in the classical
C2 domains.
This is the first evidence of the presence of a phos-
photyrosine binding domain in the structure of a protein
Ser/Thr kinase, thus directly linking tyrosine phosphor-
ylation with serine/threonine phosphorylation. Our find-
ings raise the question of whether other C2 domains
are phosphotyrosine binding domains. In terms of the
PKC family, the level of homology between all the clas-
sical and novel PKCs is around 70% for the C1 domains
and the kinase domains. On the other hand, the homol-
ogy level for the C2 domain is far less, about 45%, even
between PKCδ and PKC, another member of the novel
subfamily. The only close homolog of the C2 domain of
PKCδ is the C2 domain of PKCθ, another nPKC family
member, which has a homology of 70%. All the critical
residues that contact the optimal binding peptide are
conserved in PKCθ (Figure 3), and preliminary results
indicate that PKCθ indeed contains a phosphotyrosine
binding domain.
Among the proteins known to associate with PKCδ,
only a subset of them contains potential binding sites
for the C2 domain (i.e., sequences that contain the con-
sensus defined by the peptide library screens). Among
Cell
278Figure 5. Point Mutations in CDCP1 and
PKCδ Disrupt Their Phosphotyrosine-Depen-
dent Interaction
(A) Src and PKCδ were coexpressed with
either FLAG-tagged CDCP1 wt or CDCP1-
Y762F in U2-OS cells, and an anti-FLAG anti-
body was used for IP. Bound proteins were
detected with the indicated antibodies.
(B) Src, PKCδ, and wt CDCP1 or CDCP1 mu-
tated at the indicated sites were expressed
in U2-OS cells. Pull-downs were done using
GST-RD PKCδ or GST-SH2-SH3 Src fusion
proteins, and the bound CDCP1 was re-
vealed by immunoblot.
(C) 293 cells were transfected with plasmids
encoding for FLAG-tagged CDCP1 wt, Src,
and PKCδ wt or PKCδ lacking the C2 do-
main (C2). Immunoprecipitations were per-
formed using anti-FLAG antibodies. TCL:
total cell lysates.
(D) PKCδ wt or mutated versions of PKCδ
(H62D and R67S) were expressed in COS-7
cells and tested for their ability to bind a
phosphotyrosine library linked to beads. NP:
nonphosphorylated library (XXXYXXYX); P-Y:
phosphorylated library (XXXpYXXYX).
(E) PKCδ wt, H62D, or R67S were coex-
pressed with FLAG-tagged CDCP1 and Src,
and an anti-FLAG immunoprecipitation was
performed. Bound PKCδ was detected by
immunoblot.them is MUC1, a marker of transformed cells and a P
escaffold for PKCδ and Src that assembles a multipro-
tein complex in a way strikingly similar to CDCP1. An-
Eother potential binder is PKD, which was recently
shown to bind to and be a substrate for PKCδ (Storz et
Cal., 2004). In addition, the proteins Abl, hnRNPK, and
R
PLD2, which all have also been shown to associate with H
PKCδ, also contain a potential binding site. However, it c
is unlikely that the C2 domain mediates all the interac-
tion of PKCδ with other proteins. I
AThese studies demonstrate that a C2 domain within
sa Ser/Thr kinase constitutes a third phosphotyrosine
Rbinding domain, following the prior identifications of
e
the SH2 and the PTB domains. This likely reveals an u
interesting evolution from a widespread calcium/phos- (
lpholipid binding domain into a different binding module
aand illustrates the well-documented modification of
ecommon ancestral folds evolving to a variety of func-
tions. CDCP1, the first identified target of this new do-
Imain, has been proposed to serve as a marker for a
G
variety of malignant cells (Buhring et al., 2004; Hooper o
et al., 2003; Scherl-Mostageer et al., 2001), and Src also w
nhas a well-known involvement in the development of
stumors. This provides a high potential for relevance in
uthe biological implications of complex formations be-
e
tween this newly identified tyrosine binding domain and o
these signaling molecules. Our current efforts are di- A
vrected toward understanding the involvement of theKCδ C2 domain (and the one in PKCθ) in biological
vents.
xperimental Procedures
ell Lines
PG1 (rat parotid salivary gland cell line) (Soltoff et al., 1998), A431,
CT116, HEK293, U2-OS, and other cells were grown in standard
ulture conditions.
mmunoprecipitation and Immunoblot Analysis
nti-CDCP1 was obtained by rabbit immunization using the cyto-
olic domain of CDCP1 fused to GST (Cocalico Biologicals,
eamstown, Pennsylvania). Anti-PKCδ monoclonal (BD Biosci-
nces) and polyclonal (Santa Cruz Biotechnology) antibodies were
sed for immunoprecipitation and blotting, respectively. Anti-Src
SC-18) antibody was from Santa Cruz Biotechnology. Cells were
ysed and subjected to SDS-PAGE as previously described (Benes
nd Soltoff, 2001; Blake et al., 1999; Shanmugam et al., 1998; Zang
t al., 1997).
dentification of CDCP1
ST-RD PKCδ was used to affinity purify a 135 kDa protein (as seen
n SDS-PAGE after Coomassie staining) from A431 cells treated
ith pervanadate for 15 min in growing medium. The band was
ot seen in the GST control or when using untreated cells. Mass
pectrometry analysis of tryptic digest identified the protein as an
nknown protein, AK023834, later on shown by Scherl-Mostageer
t al. (Scherl-Mostageer et al., 2001) to be an incomplete version
f CDCP1. Full-length CDCP1 was assembled using the cDNA
K023834 (Takara Biomedicals, Japan) and the product of a re-
erse transcriptase-PCR (Hot Star Taq, Roche) corresponding from
The PKCδ C2 Domain Binds Phosphotyrosine
279the start ATG to a unique SacI site in AK023834, using mRNA from
A549 cells (Rneasy, QIAGEN).
Plasmids and Transfections
CDCP1-FLAG plasmid was constructed by PCR amplification of
full-length CDCP1. The CDCP1 mutants Y734F, Y743F, and Y762F
were obtained by PCR-based mutagenesis using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene). GST-RD of human
PKCδ was a kind gift of Dr. Donald Kufe (Dana Farber Cancer Insti-
tute, Boston). GST-C2L (1–160) and GST-C2S (1–123) from PKCδ
were obtained by standard PCR methods using the GST-RD plas-
mid as a template and inserted into pGEX vectors (Amersham). The
Src (wt and R295K mutant) and EGFP-PKCδ (wt and R378K mutant)
encoding plasmids were generously given by Dr. Joan Brugge (Har-
vard Medical School, Boston) and Dr. Pradip Majumder (Dana
Farber Cancer Institute).
Peptide Library Screening
The peptide libraries were generated by standard methods and
quality was assessed by mass spectrometry (Michael Burn, Tufts
University, Boston). The peptide libraries were screened as de-
scribed elsewhere (Songyang and Cantley, 1995b) using the regula-
tory domain (residues 1–332) of PKCδ fused to GST.
Isothermal Titration Calorimetry
ITC was performed on a VP-ITC apparatus (MicroCal, Northamp-
ton, Massachusetts) according to manufacturer instructions. The
C2 domain of PKCδ (residues 1–160) fused to GST was prepared
by affinity purification on glutathione beads. The fusion protein was
eluted from the beads using 30 mM reduced glutathione in MES
(pH 6.4), NaCl 150 mM buffer, and the eluted material was dialyzed
against MES, NaCl buffer overnight. The final concentration was
adjusted to 0.015 mM. Nonphosphorylated and phosphorylated
versions of the optimal PKCδ peptide (GGALYSIpYQPYVFAKKK)
were synthesized based on peptide library screening results and
purified by HPLC. The peptides were used at 0.15 mM. Analysis of
the data was done using Origin software.
Crystal Structure Determination
Human PKCδ (residues 1–123) was cloned into pET28 vector (No-
vagen), expressed in E. coli, and purified using Ni-NTA agarose
(QIAGEN). Five mg/ml protein containing 1 mM peptide was com-
bined in a 1:1 ratio with the reservoir solution as the hanging drop.
Crystals were obtained with 14% PEG4K, 100 mM MES (pH 6.0),
8% PEG200, 200 mM potassium acetate, and 10% glycerol as the
reservoir solution. Data were collected at CHESS F1 station and
processed with DENZO and SCALEPACK (Otwinowski and Minor,
1997). The structure was solved by molecular replacement using
CNS (Brunger et al., 1998) and 1BDY as the model. Refinement was
performed with CNS.
In Vitro Transcription and Translation
The C2 domain of PKCδ encompassing the pseudosubstrate region
(residues 1–160) or the first 100 residues corresponding to an in-
complete C2 domain (Pappa et al., 1998) were in vitro transcribed
and translated from pcDNA 3.1(+)-based plasmids (Invitrogen)
using the TNT T7 system (Promega) in the presence of 35S methio-
nine. The optimal phospho- and nonphosphopeptides synthesized
and coupled to biotin were immobilized on Ultralink streptavidin
beads (Pierce) and incubated with the products of in vitro transla-
tion. After washes in PBS 1% NP40, the bound proteins were sub-
jected to SDS-PAGE and revealed by autoradiography.
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